Selected for the Japan Patent Office's IP Acceleration Program 'IPAS2022'
Epistra Inc. has been selected as a supported company in IPAS (IP Acceleration Program for Startups), implemented by the Japan Patent Office. Through this program, we will further accelerate our efforts in the intellectual property domain.
About IPAS
This program supports startups in building IP strategies to accelerate their growth. For startups founded on innovative technologies and ideas, intellectual property is a primary asset and a source of competitive advantage.
It is important for startups to build an “IP strategy” that enables strategic utilization of intellectual property for growth, including policies on patent filing and trade secret protection, as well as policies regarding collaboration and licensing with other companies.
However, many startups lack knowledge and expertise in intellectual property, or find themselves short on resources to develop IP strategies and acquire rights due to their focus on launching the business.
In this program, an “IP Mentoring Team” is organized, consisting of business experts and IP experts with the knowledge and skills to address each participating company’s challenges and support needs. Through approximately 5 months of mentoring alongside the IP Mentoring Team, participating companies diagnose and refine their business strategies and build IP strategies aligned with them. This strongly supports startups in strategically leveraging intellectual property to accelerate growth without losing competitiveness.
Related Articles
Won Grand Prix in the 7th IP BASE AWARD Startup Category Hosted by the Japan Patent Office
On March 3, 2026, Epistra Inc. won the Grand Prix in the startup category at the '7th IP BASE AWARD' ceremony hosted by the Japan Patent Office.
Jikkenigaku Special Issue 'AI and Data-Driven Drug Discovery Research' Published — CTO Tsuzuki Authors Chapter on AI-Driven Drug Target Discovery
In 'Jikkenigaku Special Issue: AI and Data-Driven Drug Discovery Research' published by Yodosha, our CTO Taku Tsuzuki authored a chapter on AI-driven knowledge mining for drug target discovery.
Speaking Engagement: Delivered Keynote at the 10th Cell Manufacturing Kotozukuri Symposium
On March 4, 2026, CEO Yosuke Ozawa delivered a keynote speech on optimizing cell manufacturing processes using AI and robotics at the '10th Cell Manufacturing Kotozukuri Symposium' hosted by Osaka University.